Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics


Mirum Pharmaceuticals, Inc. - common stock (MIRM): $18.30

-0.19 (-1.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MIRM Stock Price Chart Interactive Chart >

Price chart for MIRM

MIRM Price/Volume Stats

Current price $18.30 52-week high $26.31
Prev. close $18.49 52-week low $13.85
Day low $17.86 Volume 363,500
Day high $19.37 Avg. volume 113,539
50-day MA $16.10 Dividend yield N/A
200-day MA $17.87 Market Cap 558.44M

Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio


Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.


MIRM Latest News Stream


Event/Time News Detail
Loading, please wait...

MIRM Latest Social Stream


Loading social stream, please wait...

View Full MIRM Social Stream

Latest MIRM News From Around the Web

Below are the latest news stories about Mirum Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIRM as an investment opportunity.

Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan

Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.

Yahoo | September 22, 2021

Mirum, Takeda Ink Maralixibat Licensing Pact In Japan

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for maralixibat in Japan for Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia (BA). Under the terms of the agreement, Takeda will be responsible for regulatory approval and commercialization of maralixibat in Japan. Takeda will also be responsible for the development, including conducting clinical stud

Yahoo | September 21, 2021

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

FOSTER CITY, Calif. & OSAKA, Japan, September 21, 2021--Mirum and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

Yahoo | September 21, 2021

Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison

FOSTER CITY, Calif., September 13, 2021--Mirum Submits European MAA for Maralixibat in ALGS Supported by New Positive Results from Natural History Study Comparison

Yahoo | September 13, 2021

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., September 10, 2021--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo | September 10, 2021

Read More 'MIRM' Stories Here

MIRM Price Returns

1-mo 12.62%
3-mo 5.84%
6-mo -11.17%
1-year -1.82%
3-year N/A
5-year N/A
YTD 4.81%
2020 -28.79%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7501 seconds.